Cavatak combines with immune checkpoint inhibitors
10 November, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) said preclinical data suggests that its Cavatak anticancer candidate performs better when combined with immune checkpoint inhibitors.
Patrys postpones PAT-SM6 trial
07 November, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has advised that complications in the manufacturing process are likely to delay the commencement of a planned trial of PAT-SM6 in multiple myeloma until 2Q15.
Potential new approach to treating diabetes
07 November, 2014Regulating beta cell stress provides a potential new approach to treating diabetes.
Prima's CVac improves OS in ovarian cancer trial
06 November, 2014 by Dylan Bushell-EmblingPrima BioMed's (ASX:PRR) CVac candidate is demonstrating a clear trend in improved overall survival in patients with second remission ovarian cancer.
STA expands PBS listing for cancer drug
03 November, 2014 by Dylan Bushell-EmblingSpecialised Therapeutics Australia's cancer drug Abraxane will now receive PBS reimbursed in metastatic pancreatic cancer, expanding its initial listing covering metastatic breast cancer.
Novogen to raise up to $7.5m in placement
03 November, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has initiated a placement to raise up to $7.5m to take Cantrixil into phase I trials in ovarian cancer and abdominal cavity cancers.
Clinical Genomics signs China partner for FIT
31 October, 2014 by Dylan Bushell-EmblingClinical Genomics has appointed BioChain Group as the exclusive Chinese distributor for its faecal immunochemical colorectal cancer screening test.
Patrys names Roger McPherson interim CEO
29 October, 2014 by Dylan Bushell-EmblingPatrys (ASX:PAB) has appointed an interim CEO to ensure an orderly transition once it chooses a permanent replacement for outgoing chief Dr Marie Roskrow.
VivaGel condoms on sale at Woolworths: Starpharma
29 October, 2014 by Dylan Bushell-EmblingStarpharma (ASX:SPL) is set to start reaping royalties from partner Ansell's sales of VivaGel coated condoms and has received a $4.2m R&D tax incentive rebate for FY14.
Alchemia shares sink on negative trial result
28 October, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has revealed that its phase III trial of HA-Irinotecan in metastatic colorectal cancer failed to meet the primary end point of an improvement of PFS against the control group.
Alchemia CSO wins Telstra businesswoman award
24 October, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) Chief Scientific Officer Dr Tracey Brown has won the Telstra Victorian Business Woman of the Year award and is now eligible to win the national award as well.
Clinical Genomics, CSIRO settle on licence terms
22 October, 2014 by Dylan Bushell-EmblingClinical Genomics and the CSIRO have signed an international licensing agreement covering their jointly developed blood test for bowel cancer.
Over $500m for NHMRC grants
22 October, 2014The Australian Government has allocated $580.2 million to fund 848 National Health and Medical Research Council (NHMRC) grants.
Novogen's Trilexium shows promise in child cancers
22 October, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) said lab studies of drug candidate Trilexium show its potential in treating paediatric diffuse pontine glioma and paediatric neuroblastoma cells.
Link between viral infection and autoimmune disease
21 October, 2014Australian scientists have discovered that common viral infections can pave the way to autoimmune disease.
